(Q42685780)

4 November 2017

title

Suboptimal use of HIV drug resistance testing in a universal health-care setting (English)

1 reference

4 November 2017

9

1 reference

4 November 2017

O Eyawo

1

0 references

author name string

K A Fernandes

2

1 reference

4 November 2017

E K Brandson

3

1 reference

4 November 2017

A Palmer

4

1 reference

4 November 2017

K Chan

5

1 reference

4 November 2017

V D Lima

6

1 reference

4 November 2017

R P Harrigan

7

1 reference

4 November 2017

J S Montaner

8

1 reference

4 November 2017

publication date

1 January 2011

1 reference

4 November 2017

1 reference

4 November 2017

volume

23

1 reference

4 November 2017

issue

1

1 reference

4 November 2017

page(s)

42-51

1 reference

HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort.

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2010.498871

Non-adherence to highly active antiretroviral therapy predicts progression to AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2010.498871

A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2010.498871

Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2010.498871

Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2010.498871

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2010.498871

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2010.498871

Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2010.498871

Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2010.498871

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2010.498871

Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2010.498871

Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2010.498871

Physician experience in the care of HIV-infected persons is associated with earlier adoption of new antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2010.498871

Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2010.498871

Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2010.498871

Impact of drug resistance mutations on virologic response to salvage therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2010.498871

Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2010.498871

Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2010.498871

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2010.498871

Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2010.498871

Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 × 109 cells/L

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2010.498871

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2010.498871

Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2010.498871

10.1080/09540121.2010.498871

21 January 2018

Identifiers

DOI

1 reference

4 November 2017

1 reference